Spark Investment Management LLC acquired a new stake in Agenus Inc. (NASDAQ:AGEN) during the second quarter, Holdings Channel reports. The institutional investor acquired 198,200 shares of the biotechnology company’s stock, valued at approximately $774,000.

Several other large investors also recently modified their holdings of AGEN. SG Americas Securities LLC increased its stake in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Agenus during the fourth quarter valued at about $143,000. American International Group Inc. increased its stake in shares of Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,984 shares in the last quarter. Quotient Investors LLC increased its stake in shares of Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 3,800 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Agenus by 203.7% in the first quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 34,833 shares in the last quarter. 42.78% of the stock is owned by institutional investors.

Agenus Inc. (NASDAQ AGEN) opened at 3.55 on Friday. The firm’s market cap is $353.98 million. The company’s 50-day moving average is $4.30 and its 200 day moving average is $3.90. Agenus Inc. has a one year low of $3.20 and a one year high of $7.49.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.04. The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $6.66 million. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. Agenus’s quarterly revenue was down 36.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) EPS. Equities analysts anticipate that Agenus Inc. will post ($1.13) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Spark Investment Management LLC Acquires New Position in Agenus Inc. (NASDAQ:AGEN)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/spark-investment-management-llc-acquires-new-position-in-agenus-inc-nasdaqagen/1476715.html.

Several brokerages have recently issued reports on AGEN. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Wednesday, July 5th. Jefferies Group LLC reissued a “buy” rating and set a $7.00 price objective on shares of Agenus in a research report on Friday, August 4th. Maxim Group reissued a “buy” rating and set a $7.00 price objective on shares of Agenus in a research report on Sunday, April 23rd. HC Wainwright set a $5.00 price objective on shares of Agenus and gave the stock a “hold” rating in a research report on Saturday, May 6th. Finally, ValuEngine downgraded shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $5.88.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.